These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 28332624

  • 21. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y.
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [Abstract] [Full Text] [Related]

  • 22. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
    Yao S, Zhi X, Wang R, Qian K, Hu M, Zhang Y.
    Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
    [Abstract] [Full Text] [Related]

  • 23. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 24. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J, Zhang Q, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2015 Dec 06; 18(12):734-9. PubMed ID: 26706949
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R, Hua L, Wenlong G, Shuanying Y.
    Oncotarget; 2016 Dec 27; 7(52):86902-86913. PubMed ID: 27893423
    [Abstract] [Full Text] [Related]

  • 29. Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
    Zhu Z, Chai Y.
    Thorac Cancer; 2016 Nov 27; 7(6):681-683. PubMed ID: 27807951
    [Abstract] [Full Text] [Related]

  • 30. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
    Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ.
    Int J Radiat Oncol Biol Phys; 2014 Jun 01; 89(2):322-9. PubMed ID: 24679729
    [Abstract] [Full Text] [Related]

  • 31. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
    Li X, Yang XJ, Sun YF, Qin N, Lü JL, Wu YH, Zhang H, Zhang Q, Zhang SC.
    Zhonghua Zhong Liu Za Zhi; 2012 Aug 01; 34(8):627-31. PubMed ID: 23159001
    [Abstract] [Full Text] [Related]

  • 32. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Chih-Hsin Yang J, Yu CJ.
    Oncologist; 2017 Sep 01; 22(9):1075-1083. PubMed ID: 28507206
    [Abstract] [Full Text] [Related]

  • 33. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
    Soon YY, Leong CN, Koh WY, Tham IW.
    Radiother Oncol; 2015 Feb 01; 114(2):167-72. PubMed ID: 25583566
    [Abstract] [Full Text] [Related]

  • 34. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S, Hu X, Wang Y, Li J, Zhou L, Hao X, Liu Y, Shi Y.
    Asia Pac J Clin Oncol; 2019 Jun 01; 15(3):166-171. PubMed ID: 30311393
    [Abstract] [Full Text] [Related]

  • 35. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J.
    Lung Cancer; 2011 Aug 01; 73(2):195-202. PubMed ID: 21144613
    [Abstract] [Full Text] [Related]

  • 36. [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line 
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
    Yao S, Qian K, Wang R, Li Y, Zhang Y.
    Zhongguo Fei Ai Za Zhi; 2015 Jun 01; 18(6):369-73. PubMed ID: 26104894
    [Abstract] [Full Text] [Related]

  • 37. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
    Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D, Kong R, Chen Z, Sun J.
    Clin Transl Oncol; 2018 Mar 01; 20(3):366-373. PubMed ID: 28776311
    [Abstract] [Full Text] [Related]

  • 38. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, Zhang J.
    J Thorac Oncol; 2016 Oct 01; 11(10):1718-28. PubMed ID: 27237825
    [Abstract] [Full Text] [Related]

  • 39. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
    Jiang Z, Zhang J, Sun H, Wang C, Zhang Y, Li Y, Pan Z.
    Thorac Cancer; 2021 Sep 01; 12(17):2369-2374. PubMed ID: 34255422
    [Abstract] [Full Text] [Related]

  • 40. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM, Cooper BT, Chachoua A, Butler J, Donahue B, Silverman JS, Kondziolka D.
    J Neurooncol; 2016 Feb 01; 126(3):483-91. PubMed ID: 26520640
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.